nach oben

Erschienen in:

01.08.2012 | Original Article

Serum Metabolic Profiling in Inflammatory Bowel Disease

verfasst von: Horace R. T. Williams, James D. Willsmore, I. Jane Cox, David G. Walker, Jeremy F. L. Cobbold, Simon D. Taylor-Robinson, Timothy R. Orchard

Erschienen in: Digestive Diseases and Sciences | Ausgabe 8/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

The inflammatory bowel diseases (IBD), Crohn’s disease (CD), and ulcerative colitis (UC), are chronic inflammatory conditions of the gastrointestinal tract whose pathogenesis is not completely understood. ¹H nuclear magnetic resonance (NMR) spectroscopy of serum generates comprehensive metabolic profiles, reflecting systemic metabolism, which may be altered in disease states.

Aim

The aim of this study was to use ¹H NMR-based serum metabolic profiling in the investigation of CD patients, UC patients, and controls, potentially to provide insights into disordered metabolism in IBD, and into underlying mechanisms of disease.

Methods

Serum metabolic profiles were acquired from 67 individuals (24 CD patients, 20 UC patients, and 23 healthy controls). The multivariate pattern-recognition techniques of principal components analysis (PCA) and partial least squares discriminant analysis with orthogonal signal correction (OSC-PLS-DA) were used to investigate differences between cohorts.

Results

OSC-PLS-DA distinguished CD and UC cohorts with significant predictive accuracy, highlighting differences in lipid and choline metabolism. Metabolic profiles of both CD and UC cohorts, and the combined IBD cohort, differed significantly from controls: metabolites of importance in the OSC-PLS-DA models included lipoproteins (especially HDL cholesterol), choline, N-acetylglycoprotein, and amino acids.

Conclusions

¹H NMR-based metabolic profiling has identified distinct differences in serum metabolic phenotype between CD and UC patients, as well as between IBD patients and controls.

Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28:573–621.PubMedCrossRef

Shih DQ, Targan SR. Insights into IBD pathogenesis. Curr Gastroenterol Rep. 2009;11:473–480.PubMedCrossRef

Nicholson JK, Lindon JC, Holmes E. “Metabonomics”: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999;29:1181–1189.PubMedCrossRef

Nicholson JK, Holmes E, Wilson ID. Gut microorganisms, mammalian metabolism and personalized health care. Natl Rev Microbiol. 2005;3:431–438.CrossRef

Williams HR, Cox IJ, Walker DG, et al. Characterization of inflammatory bowel disease with urinary metabolic profiling. Am J Gastroenterol. 2009;104:1435–1444.PubMedCrossRef

Marchesi JR, Holmes E, Khan F, et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res. 2007;6:546–551.PubMedCrossRef

Jansson J, Willing B, Lucio M, et al. Metabolomics reveals metabolic biomarkers of Crohn’s disease. PLoS ONE. 2009;4:e6386.PubMedCrossRef

Bjerrum JT, Nielsen OH, Hao F, et al. Metabonomics in ulcerative colitis: diagnostics, biomarker identification, and insight into the pathophysiology. J Proteome Res. 2010;9:954–962.PubMedCrossRef

Bezabeh T, Somorjai RL, Smith IC, Nikulin AE, Dolenko B, Bernstein CN. The use of ¹H magnetic resonance spectroscopy in inflammatory bowel diseases: distinguishing ulcerative colitis from Crohn’s disease. Am J Gastroenterol. 2001;96:442–448.PubMedCrossRef

10.

Lin HM, Helsby NA, Rowan DD, Ferguson LR. Using metabolomic analysis to understand inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:1021–1029.PubMedCrossRef

11.

Nicholson JK, Foxall PJ, Spraul M, Farrant RD, Lindon JC. 750 MHz ¹H and ¹H–¹³C NMR spectroscopy of human blood plasma. Anal Chem. 1995;67:793–811.PubMedCrossRef

12.

Teahan O, Gamble S, Holmes E, et al. Impact of analytical bias in metabonomic studies of human blood serum and plasma. Anal Chem. 2006;78:4307–4318.PubMedCrossRef

13.

Bertini I, Calabro A, De Carli V, et al. The metabonomic signature of celiac disease. J Proteome Res. 2009;8:170–177.PubMedCrossRef

14.

Lauridsen MB, Bliddal H, Christensen R, et al. ¹H NMR spectroscopy-based interventional metabolic phenotyping: a cohort study of rheumatoid arthritis patients. J Proteome Res. 2010;9:4545–4553.PubMedCrossRef

15.

MacIntyre DA, Jimenez B, Lewintre EJ, et al. Serum metabolome analysis by ¹H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups. Leukemia. 2010;24:788–797.PubMedCrossRef

16.

Martin FP, Rezzi S, Philippe D, et al. Metabolic assessment of gradual development of moderate experimental colitis in IL-10-deficient mice. J Proteome Res. 2009;8:2376–2387.PubMedCrossRef

17.

Chen C, Shah YM, Morimura K, et al. Metabolomics reveals that hepatic stearoyl-CoA desaturase 1 downregulation exacerbates inflammation and acute colitis. Cell Metab. 2008;7:135–147.PubMedCrossRef

18.

Stange EF, Travis SP, Vermeire S, et al. European evidence-based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. Gut. 2006;55:i1–i15.PubMedCrossRef

19.

Stange EF, Travis SP, Vermeire S, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis. 2008;2:1–23.PubMedCrossRef

20.

Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5–36.PubMed

21.

Lenz EM, Bright J, Wilson ID, et al. A ¹H NMR-based metabonomic study of urine and plasma samples obtained from healthy human subjects. J Pharm Biomed Anal. 2003;33:1103–1115.PubMedCrossRef

22.

O’Sullivan A, Gibney MJ, Brennan L. Dietary intake patterns are reflected in metabolomic profiles: potential role in dietary assessment studies. Am J Clin Nutr. 2011;93:314–321.PubMedCrossRef

23.

Harvey RF, Bradshaw JM. A simple index of Crohn’s disease activity. Lancet. 1980;1:514.PubMedCrossRef

24.

Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut. 1998;43:29–32.PubMedCrossRef

25.

Wishart DS, Tzur D, Knox C, et al. HMDB: the human metabolome database. Nucleic Acids Res. 2007;35:D521–D526.PubMedCrossRef

26.

Holmes E, Tsang TM, Huang JT, et al. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med. 2006;3:e327.PubMedCrossRef

27.

Sussulini A, Prando A, Maretto DA, et al. Metabolic profiling of human blood serum from treated patients with bipolar disorder employing ¹H NMR spectroscopy and chemometrics. Anal Chem. 2009;81:9755–9763.PubMedCrossRef

28.

Mao H, Wang H, Wang B, et al. Systemic metabolic changes of traumatic critically ill patients revealed by an NMR-based metabonomic approach. J Proteome Res. 2009;8:5423–5430.PubMedCrossRef

29.

Eriksson L, Trygg J, Wold S. CV-ANOVA for significance testing of PLS and OPLS^® models. J Chemomet. 2008;22:594–600.CrossRef

30.

Kochhar S, Jacobs DM, Ramadan Z, Berruex F, Fuerholz A, Fay LB. Probing gender-specific metabolism differences in humans by nuclear magnetic resonance-based metabonomics. Anal Biochem. 2006;352:274–281.PubMedCrossRef

31.

Kristjansson G, Venge P, Wanders A, Loof L, Hallgren R. Clinical and subclinical intestinal inflammation assessed by the mucosal patch technique: studies of mucosal neutrophil and eosinophil activation in inflammatory bowel diseases and irritable bowel syndrome. Gut. 2004;53:1806–1812.PubMedCrossRef

32.

Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103:162–169.PubMedCrossRef

33.

Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427–434.PubMedCrossRef

34.

Spoettl T, Hausmann M, Klebl F, et al. Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients. Inflamm Bowel Dis. 2007;13:727–732.PubMedCrossRef

35.

Friedman G, Barak V, Chajek-Shaul T, et al. Recombinant human interleukin-1 suppresses lipoprotein lipase activity, but not expression of lipoprotein lipase mRNA in mesenchymal rat heart cell cultures. Biochim Biophys Acta. 1991;1089:83–87.PubMedCrossRef

36.

Querfeld U, Ong JM, Prehn J, et al. Effects of cytokines on the production of lipoprotein lipase in cultured human macrophages. J Lipid Res. 1990;31:1379–1386.PubMed

37.

Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res. 1996;37:693–707.PubMed

38.

Ripolles Piquer B, Nazih H, Bourreille A, et al. Altered lipid, apolipoprotein, and lipoprotein profiles in inflammatory bowel disease: consequences on the cholesterol efflux capacity of serum using Fu5AH cell system. Metabolism. 2006;55:980–988.PubMedCrossRef

39.

Levy E, Rizwan Y, Thibault L, et al. Altered lipid profile, lipoprotein composition, and oxidant and antioxidant status in pediatric Crohn disease. Am J Clin Nutr. 2000;71:807–815.PubMed

40.

Hyka N, Dayer JM, Modoux C, et al. Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood. 2001;97:2381–2389.PubMedCrossRef

41.

Zeisel SH, Blusztajn JK. Choline and human nutrition. Ann Rev Nutr. 1994;14:269–296.CrossRef

42.

Nassif A, Longo WE, Mazuski JE, Vernava AM, Kaminski DL. Role of cytokines and platelet-activating factor in inflammatory bowel disease. Implications for therapy. Dis Colon Rectum. 1996;39:217–223.PubMedCrossRef

43.

Niculescu MD, Da Costa KA, Fischer LM, Zeisel SH. Lymphocyte gene expression in subjects fed a low-choline diet differs between those who develop organ dysfunction and those who do not. Am J Clin Nutr. 2007;86:230–239.PubMed

44.

Zeisel SH. Is there a new component of the Mediterranean diet that reduces inflammation? Am J Clin Nutr. 2008;87:277–278.PubMed

45.

Mehta AK, Singh BP, Arora N, Gaur SN. Choline attenuates immune inflammation and suppresses oxidative stress in patients with asthma. Immunobiology. 2010;215:527–534.PubMedCrossRef

46.

Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–454.PubMedCrossRef

47.

Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426–431.PubMedCrossRef

48.

Lanfranchi GA, Brignola C, Campieri M, et al. Assessment of nutritional status in Crohn’s disease in remission or low activity. Hepatogastroenterology. 1984;31:129–132.PubMed

49.

Hollander D. Intestinal permeability, leaky gut, and intestinal disorders. Curr Gastroenterol Rep. 1999;1:410–416.PubMedCrossRef

50.

Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134:577–594.PubMedCrossRef

51.

Velagapudi VR, Hezaveh R, Reigstad CS, et al. The gut microbiota modulates host energy and lipid metabolism in mice. J Lipid Res. 2010;51:1101–1112.PubMedCrossRef

52.

Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457:480–484.PubMedCrossRef

53.

Dumas ME, Barton RH, Toye A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci USA. 2006;103:12511–12516.PubMedCrossRef

Titel: Serum Metabolic Profiling in Inflammatory Bowel Disease
verfasst von: Horace R. T. Williams
James D. Willsmore
I. Jane Cox
David G. Walker
Jeremy F. L. Cobbold
Simon D. Taylor-Robinson
Timothy R. Orchard
Publikationsdatum: 01.08.2012
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 8/2012
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-012-2127-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Serum Metabolic Profiling in Inflammatory Bowel Disease

Abstract

Background

Aim

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Background

Aim

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2012

Protective Effects of 3,4-Oxo-isopropylidene-Shikimic Acid on Experimental Colitis Induced by Trinitrobenzenesulfonic Acid in Rats

Performance of the Fecal Immunochemical Test Is Not Decreased by High Ambient Temperature in the Rapid Return System

A Water-Jet Videoendoscope May Reduce Operation Time of Endoscopic Submucosal Dissection for Early Gastric Cancer

An Ex Vivo Bacteriologic Study Comparing Antiseptic Techniques for Natural Orifice Translumenal Endoscopic Surgery (NOTES) via the Gastrointestinal Tract

Elevated Fecal Short Chain Fatty Acid and Ammonia Concentrations in Children with Autism Spectrum Disorder

Fecal M2-PK in Children with Crohn’s Disease: A Preliminary Report

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin